Santen Pharmaceutical has developed a monoclonal antibody with high affinity for VEGF, crucial for treating eye diseases. The antibody binds to VEGF with a dissociation constant of 1×10-11 mol/L or less, offering potential advancements in medical treatment. GlobalData’s report on Santen Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Santen Pharmaceutical, Nanoparticle drug conjugates was a key innovation area identified from patents. Santen Pharmaceutical's grant share as of February 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
Monoclonal antibody with high affinity for vegf
A recently granted patent (Publication Number: US11872271B2) discloses a monoclonal antibody against Vascular Endothelial Growth Factor (VEGF) and its antigen-binding fragment. The antibody is designed with specific amino acid sequences in its complementarity-determining regions (CDRs) to bind to VEGF and inhibit its interaction with VEGF receptors, VEGFR1 and VEGFR2. The antibody can be a chimeric, humanized, or caninized antibody, with heavy and light chain constant regions derived from human or canine IgG1 and IgGB, respectively.
Moreover, the patent covers the use of this monoclonal antibody in treating VEGF-mediated cancers and eye diseases. By administering the antibody to patients in need, the method aims to inhibit pathological angiogenesis and vascular hyperpermeability associated with conditions like colorectal cancer, diabetic retinopathy, and age-related macular degeneration. The antibody's efficacy is measured by its ability to bind to VEGF with a dissociation constant of 1×10-11 mol/L or less, highlighting its specificity and potential therapeutic value in various solid cancers and eye diseases. The patent also includes the production of the antibody through a hybridoma, pharmaceutical compositions containing the antibody, and kits for its use in research and clinical settings.
To know more about GlobalData’s detailed insights on Santen Pharmaceutical, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
